Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.49 |
| ▸ | MTOR | P42345 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12110268 | 0.95 | KMT2A (0.56) | KDM4EHTTMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL15386410 | 0.92 | ALDH1A1 (0.62) | KDM4EHTTMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL22838501 | 0.89 | KDM4E (0.49) | KDM4EHTTMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL8973821 | 0.88 | HTT (0.63) | KDM4EHTTMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL2689185 | 0.86 | KMT2A (0.49) | KDM4EHTTMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL912709 | 0.86 | MAPT (0.54) | KDM4EHTTMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL17309194 | 0.86 | HRH4 (0.66) | KDM4EHTTSMN1; SMN2KMT2APIK3CA | |
| SCHEMBL9418611 | 0.85 | HTT (0.61) | KDM4EHTTMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL22838503 | 0.84 | PIK3CA (0.48) | KDM4EHTTMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL12110270 | 0.83 | SMN1; SMN2 (0.50) | KDM4EHTTMAPK1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218358-B1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIQUR THERAPEUTICS AG (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| EP-0356412-B1 | USE OF 2-AMINO-4-MORPHOLINO-6-PROPYL-1,3,5-TRIAZINES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE AND MENTAL DISORDERS | U C B, S.A. (BE) | 1992-05-13 | — | — | EP | disclosed |
| EP-0356413-B1 | 2-AMINO-4-MORPHOLINO-6-PROPYL-1,3,5-TRIAZINES | U C B, S.A. (BE) | 1992-01-29 | — | — | EP | disclosed |
| US-4956363-A | 2-amino-4-morpholino-6-propyl-1,3,5-triazine | U C B S.A. (BE) | 1990-09-11 | — | — | US | disclosed |
| US-4956367-A | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE | U C B S.A. (BE) | 1990-09-11 | — | — | US | disclosed |
| EP-0356412-A1 | Use of 2-amino-4-morpholino-6-propyl-1,3,5-triazines in the preparation of a medicament for the treatment of cognitive and mental disorders | U C B, S.A. (BE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0356413-A1 | 2-Amino-4-morpholino-6-propyl-1,3,5-triazines | U C B, S.A. (BE) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | KDM4E 3825/4885HTT 3381/4885MAPK1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.